date:May 10, 2012
trengthening of the Swiss franc in 2011 was mitigated by a 50million currency hedge gain, a benefit which will not be repeated in 2012. Despite this, DSM anticipates that it will make further progress, with EBITDA expected to be above 2011,it said.
Pharma performance,remained weak, although first signs of improvement are visible.
Emerging markets were praised as compensation for the poor polymers performance.Net sales in China amounted to USD 456 million (352m), which is at the same level as